Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Prince, 8, is handed a certificate confirming he is Ebola-free, outside an Ebola treatment center in Beni, DRC. Photo: Sally Hayden/SOPA Images/LightRocket via Getty Images

Public health officials announced Monday they had gathered enough preliminary data to determine that 2 of the 4 investigational treatments for Ebola performed better than the others. The current trial in the Democratic Republic of the Congo has been dropped to focus on a new extension trial for the 2 monoclonal antibodies.

Why it matters: There are currently no FDA-approved treatments for Ebola. Researchers testing drugs during the DRC's largest outbreak found a cocktail of 3 antibodies called REGN-EB3 was most effective, followed closely by monoclonal antibody 114.

"From now on, we will no longer have to say Ebola is untreatable [if caught early enough]."
— Jean-Jacques Muyembe-Tamfum, head of DRC's Ebola response, at press conference

Background: Four treatments — ZMapp, mAb114, remdesivir (GS-5734), and REGN-EB3 (REGN3470-3471-3479) — began undergoing randomized, controlled testing on Nov. 20 through an international research consortium arranged by the World Health Organization and co-led by the National Institute of Allergy and Infectious Disease.

What's new: NIAID director Anthony Fauci says the trial that ended Friday offered preliminary data showing mortality rates as follows: ZMapp at 49%, remdesivir at 53%, REGN-EB3 at 29%, and mAb114 was 34%. This compares with an estimated 67% overall mortality rate for untreated cases.

  • "The early stopping criteria [of the trial] was met by Regeneron [REGN-EB3]," Fauci said, when compared to the control, ZMapp.
  • Fauci warned that the numbers are still early: "More stringent data will be coming." For instance, roughly 15% of the participants in the study had received an experimental Ebola vaccine as well, and they aren't sure yet if that skewed the effect.
  • Both drugs block a particular component of the virus, Fauci added.
  • Regeneron Pharmaceuticals developed REGN-EB3 using mouse-generated antibodies that were then produced in specialized bioreactors. NIAID developed mAb114 from antibodies from an Ebola survivor, and granted a license to Ridgeback Biotherapeutics.

Meanwhile, as of Saturday, the WHO reported 2,816 cases (2,722 confirmed and 94 probable), including 1,888 deaths.

  • WHO's Mike Ryan, who was also at the press briefing, warned that although "the news today is fantastic," the complex scenario of insecurity and community distrust on the ground requires renewed efforts by the international security to offer help to the region.
  • "Too many people are not going to the Ebola Treatment Centers early enough," Ryan said, adding that he hopes the news will entice more people to come to ETCs earlier.
  • All ETCs will start offering both treatments.

Go deeper:

Editor's note: This piece was corrected to reflect the different ways the 2 treatments were developed (showing Regeneron did not use antibodies from an Ebola survivor).

Go deeper

U.S. sounds alarm on Ukraine

Conscripts line up at a Russian railway station yesterday before departing for Army service. Photo: Sergei Malgavko/TASS via Getty Images

The Biden administration is "deeply concerned" by new intelligence — detailed for Axios and other outlets — showing Russia stepping up preparations to invade Ukraine as soon as early 2022.

Why it matters: Most of this was known from public sources and satellite imagery, but the administration is sending a stronger signal by releasing specific details from the intelligence community.

Felix Salmon, author of Capital
48 mins ago - Economy & Business

Philanthropy in the age of crypto

Illustration: Annelise Capossela/Axios

The best charities are increasingly effective. That's the clear message sent by Open Philanthropy, the think tank that doubles as the grant-making vehicle for Facebook co-founder Dustin Moskovitz and his wife Cari Tuna.

Why it matters: With tech and crypto wealth becoming a fast-growing part of the philanthropic pie, there's more of an emphasis than ever on effectiveness — what the newly-divorced Melinda French Gates, in her recent Giving Pledge update, characterizes as giving as "impactfully as possible."

4 hours ago - Health

Prior coronavirus infections may not protect well against Omicron

Illustration: Aïda Amer/Axios

New data from South Africa suggests the Omicron variant spreads more than twice as quickly as the Delta variant, and that immunity from prior infection doesn't appear to protect a person very well against Omicron variant.

Why it matters: The findings are extremely preliminary, and there are still many open questions about how well vaccines work against the variant. But these initial breadcrumbs of data are helping the world begin to understand what it's up against.